	Item	Guidance for Reporting	Reported in section	
TITLE			2000	
Title	1	Identify the study as an economic evaluation and specify the	Page 1	
		interventions being compared.	i age i	
ABSTRACT		Provide a structured summary that highlights context, key methods,		
Abstract	2	results and alternative analyses.	Page 2	
INTRODUCTION	•	•		
Background and	3	Give the context for the study, the study question and its practical	Page 2-3	
objectives METHODS		relevance for decision making in policy or practice.	r age z o	
Health economic		Indicate whether a health economic analysis plan was developed and	1	
analysis plan	4	where available.	NA	
Study population	5	Describe characteristics of the study population (such as age	Page 3-4	
		range, demographics, socioeconomic, or clinical characteristics).	Page 2-3, 13-14	
Setting and location Comparators	6 7	Provide relevant contextual information that may influence findings. Describe the interventions or strategies being compared and why chosen.	Page 2-3, 13-14 Page 4	
Perspective	8	State the perspective(s) adopted by the study and why chosen.	Page 3	
Time horizon	9	State the time horizon for the study and why appropriate.	Page 3-4	
Discount rate	10		Page 6	
Colordian of cut		Describe what outcomes were used as the measure(s) of benefit(s)	1_	
Selection of outcomes	11	and harm(s).	Page 7-8	
Measurement of		Describe how outcomes used to capture benefit(s) and harm(s)		
outcomes	12	were measured.	Page 7-8	
Valuation of outcomes	13	Describe the population and methods used to measure and value outcomes.	Page 4-8	
Measurement and				
valuation of resources and costs	14	Describe how costs were valued.	Page 6	
Currency, price date,		Report the dates of the estimated resource quantities and unit costs, plus the		
and conversion	15		Page 6	
Rationale and	16	If modelling is used, describe in detail and why used. Report if the model	Page 3, Ap	nandiy 1
description of model	10	is publicly available and where it can be accessed.	raye 3, Ap	pendix
Analytics and assumptions	17	Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used.	Page 3, A	ppendix
Characterizing	4.0	Describe any methods used for estimating how the results of the study		
heterogeneity	18	vary for sub-groups.	NA / Page	4, 8
Characterizing	19	Describe how impacts are distributed across different individuals	NA	
distributional effects Characterizing		or adjustments made to reflect priority populations.		
uncertainty	20	Describe methods to characterize any sources of uncertainty in the analysis.	Page 8	
Approach to		Describe any approaches to engage patients or service recipients, the		
engagement with	21	general public, communities, or stakeholders (e.g., clinicians or payers) in		
patients and others affected by the study		the design of the study.	NA	
RESULTS				
	00	Report all analytic inputs (e.g., values, ranges, references) including	Danie C	
Study parameters	22	uncertainty or distributional assumptions.	Page 6	
Summary of main	23	Report the mean values for the main categories of costs and outcomes of	Page 8-11	
results		interest and summarise them in the most appropriate overall measure. Describe how uncertainty about analytic judgments, inputs, or projections	r age o r	
Effect of uncertainty	24	affect findings. Report the effect of choice of discount rate and time horizon,		
,		if applicable.	Page 10,	12
Effect of engagement		Report on any difference patient/service recipient, general public, community,		
with patients and others affected by the study	25	or stakeholder involvement made to the approach or findings of the study	NA	
DISCUSSION			107	
Study findings,			D 40	
limitations,	0.0	Report key findings, limitations, ethical or equity considerations not captured,	Page 13-1	14
generalizability, and	26	and how these could impact patients, policy, or practice.		
current knowledge				
OTHER RELEVANT INFO	RMATIC			
Source of funding	27	Describe how the study was funded and any role of the funder in	Page 1	
Ü		the identification, design, conduct, and reporting of the analysis Report authors conflicts of interest according to journal or	Page 1	
Conflicts of interest	28			

1

Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins CD, Petrou S, Pwu RF, Staniszewska S; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. BMJ. 2022;376:e067975.

The checklist is Open Access distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/.